Synovial Sarcoma, X Breakpoint 6 (Pseudogene) (SSX6) Peptide
SSX6
Reactivity: Mammalian
Host: Synthetic
BP, WB, IHC
Catalog No. ABIN939479
Quick Overview for Synovial Sarcoma, X Breakpoint 6 (Pseudogene) (SSX6) Peptide (ABIN939479)
Target
SSX6
(Synovial Sarcoma, X Breakpoint 6 (Pseudogene) (SSX6))
Origin
Mammalian
Source
Synthetic
Application
Blocking Peptide (BP), Western Blotting (WB), Immunohistochemistry (IHC)
-
-
Peptide Type
- Synthetic
-
Sequence
- IPKIMPEKPA EEGSDSKGVP EASGPQNDGK KLCPPGKASS SEKIHERSGP
-
Characteristics
-
A synthetic peptide for use as a blocking control in assays to test for specificity of SSX6 antibody,
Alternative Names: SSX6 control peptide, SSX6 antibody Blocking Peptide, Anti-SSX6 Blocking Peptide, synovial sarcoma, X breakpoint 6 Blocking Peptide, dJ54B20.1 Blocking Peptide, SSX6, SSX-6, SSX 6, SSX-6 Blocking Peptide, SSX 6 Blocking Peptide
-
-
-
-
Application Notes
- Optimal conditions should be determined by the investigator
-
Restrictions
- For Research Use only
-
-
-
Format
- Lyophilized
-
Reconstitution
- Add 100 µL of distilled water for a final peptide concentration is 1 mg/mL.
-
Buffer
- PBS
-
Handling Advice
- Avoid repeated freeze/thaw cycles.
-
Storage
- -20 °C
-
Storage Comment
- Store at -20 °C long term.
-
-
- SSX6 (Synovial Sarcoma, X Breakpoint 6 (Pseudogene) (SSX6))
-
Background
- SSX6 belongs to the family of highly homologous synovial sarcoma X (SSX) breakpoint proteins. These proteins may function as transcriptional repressors. They are also capable of eliciting spontaneously humoral and cellular immune responses in cancer patients, and are potentially useful targets in cancer vaccine-based immunotherapy.
-
Molecular Weight
- 22 kDa
Target
-
You are here:
